| 0.571 -0.029 (-4.83%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.74  |
1-year : | 0.89 |
| Resists | First : | 0.64 |
Second : | 0.76 |
| Pivot price | 0.52 |
|||
| Supports | First : | 0.43 | Second : | 0.35 |
| MAs | MA(5) : | 0.55 |
MA(20) : | 0.52 |
| MA(100) : | 1.15 |
MA(250) : | 1.65 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 77.2 |
D(3) : | 71.8 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 3.26 | Low : | 0.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TRAW ] has closed below upper band by 21.4%. Bollinger Bands are 72% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.62 - 0.62 | 0.62 - 0.62 |
| Low: | 0.56 - 0.57 | 0.57 - 0.57 |
| Close: | 0.57 - 0.57 | 0.57 - 0.58 |
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Fri, 14 Aug 2026
Ikarian Capital (TRAW) reports 1.56M-share, 9.5% beneficial stake in Traws Pharma - Stock Titan
Fri, 14 Aug 2026
TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high - TradingView
Fri, 14 Aug 2026
Traws Pharma Expects Q3 Resubmission for Flu Antiviral - Stock Titan
Fri, 14 Aug 2026
Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A - Stock Titan
Fri, 14 Aug 2026
Sirenia Capital (TRAW) discloses warrant-based stake capped at 9.9% ownership - Stock Titan
Thu, 13 Aug 2026
Traws Pharma Inc (NASDAQ: TRAW) Share Price, TRAW Stock News, TRAW Share Price & Updates - Kalkine
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 1.174e+007 (%) |
| Held by Institutions | 5.3 (%) |
| Shares Short | 1,130 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.951e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -717.9 % |
| Return on Assets (ttm) | -90.1 % |
| Return on Equity (ttm) | -5 % |
| Qtrly Rev. Growth | 2.73e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 409.73 |
| EBITDA (p.s.) | 1.75e+006 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.72 |
| Dividend | 0 |
| Forward Dividend | 699850 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|